Colorado could cap payments for Amgen’s Enbrel

Colorado could soon cap how much the state will pay for Amgen’s autoimmune drug Enbrel — in what would be the first such move from a state prescription drug affordability board. Affordability boards have been around for years, but they’ve been slow to actually act on lowering costs for patients.